| Business Summary | | Biotech
Holdings
Ltd.
is
a
Vancouver-based
vertically
integrated
pharmaceutical
company
engaged
in
the
research,
development,
manufacture
and
marketing
of
pharmaceutical,
personal
care
and
health
products.
The
focus
of
the
Company
is
the
manufacturing
and
international
marketing
of
DIAB
II,
a
new
drug
for
the
treatment
of
Type
II
Diabetes.
DIAB
II
is
the
first
drug
to
be
developed
by
Biotech.
It
is
a
potent
member
of
a
new
class
of
anti-diabetic
agents
and
is
taken
as
a
small
tablet
twice
per
day.
In
addition
to
DIAB
II,
the
Company
also
develops
and
markets
over-the-counter
drugs
and
topical
creams
and
lotions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Biotech
Holdings
Ltd.
is
engaged
in
research,
development,
manufacture
and
marketing
of
pharmaceutical,
personal
care
and
health
care
products.
For
the
six
months
ended
9/30/00,
total
revenues
increased
47%
to
C$1.2
million.
Net
loss
before
U.S.
GAAP
decreased
16%
to
C$1.2
million.
Revenues
reflect
an
increase
in
sales
in
the
Company's
Personal
Care
Products
Division.
Net
loss
was
partially
offset
by
increased
S/G/A
and
interest
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Robert Rieveley | Chairman,
Pres, CEO | Lorne Brown | CFO | Gale Belding | Exec.
VP, Director | Norm Banks | VP
of Sales and Marketing | Ping Sun, M.D. | VP-R&D |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|